AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2540
-0.0044 (-1.70%)
At close: Aug 24, 2026, 4:00 PM EDT
0.2566
+0.0026 (1.02%)
After-hours: Aug 24, 2026, 6:05 PM EDT
AIM ImmunoTech Employees
As of December 31, 2025, AIM ImmunoTech had 21 total employees, including 19 full-time and 2 part-time employees. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
$4,524
Profits / Employee
-$679,524
Market Cap
7.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -2 | -8.70% | 19 | 2 |
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Azitra | 13 |
| Aprea Therapeutics | 8 |
| CNS Pharmaceuticals | 8 |
| Ernexa Therapeutics | 7 |
| Immuron | 7 |
| Traws Pharma | 7 |
| Alzamend Neuro | 6 |
| Can-Fite BioPharma | 5 |
AIM News
- 12 days ago - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article - GlobeNewsWire
- 17 days ago - AIM ImmunoTech Quarterly report: Q2 2026 - Filings
- 17 days ago - AIM ImmunoTech Earnings release: Q2 2026 - Filings
- 21 days ago - AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Proxy statement: Proxy filing - Filings
- 2 months ago - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones - GlobeNewsWire
- 2 months ago - AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences - Business Wire